Sonrotoclax and dexamethasone with or without daratumumab for AL amyloidosis with t(11;14)
Treatments studied
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new drug combination for people with a specific type of AL amyloidosis (light chain amyloidosis) that has a genetic marker called t(11;14). The treatment includes Sonrotoclax (a targeted therapy) plus steroids, and possibly another drug called daratumumab, to see if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary AL amyloidosis (a protein disorder).
- You are 18 years or older.
- A genetic test (FISH) shows you have the t(11;14) change in your cells.
- You are able to do daily activities without major limitations (ECOG score 0-2).
- Your disease can be measured through blood tests showing abnormal protein levels.
- Your heart, liver, kidneys, and blood counts are working well enough (specific lab values needed).
- You have not taken a BCL-2 inhibitor before (like venetoclax).
- You do not have active multiple myeloma or other advanced cancers.
- You are not pregnant, breastfeeding, or planning pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs for people newly diagnosed with AL amyloidosis. You may qualify if you have a specific genetic marker (t(11;14)) and your organs are working well enough.
This study tests a new combination of medicines (daratumumab, bortezomib, and dexamethasone) as the first treatment for people with a specific type of amyloidosis (AL amyloidosis). It aims to see if this combination works better than standard care.
This trial tests a new drug (SCTC21C) combined with three standard chemotherapy medicines for people who have just been diagnosed with AL amyloidosis. The goal is to see if adding the new drug helps reduce the abnormal protein deposits better than the standard treatment alone.
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
This study tests a new drug that targets two proteins on the cells causing amyloidosis, aiming to reduce the harmful protein buildup in the body. It is for people who have just been diagnosed with this condition and have not yet had other treatments for it.
This trial tests a new drug called teclistamab for people with AL amyloidosis whose disease has not responded well to previous treatments. It aims to see if the drug can help control the disease.
Hear when a new AL Amyloidosis (AL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.